Acura Pharmaceuticals, Inc. is a drug delivery company, which engages in the research, development, and commercialization of technologies and products intended to address safe use of medications. The company is headquartered in Palatine, Illinois. The company went IPO on 2000-09-12. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.
Follow-Up Questions
Who is the CEO of Acura Pharmaceuticals Inc?
Mr. Robert Jones is the President of Acura Pharmaceuticals Inc, joining the firm since 2008.
What is the price performance of ACUR stock?
The current price of ACUR is $0.0002, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Acura Pharmaceuticals Inc?
Acura Pharmaceuticals Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Acura Pharmaceuticals Inc market cap?
Acura Pharmaceuticals Inc's current market cap is $13269.999800000001
